Provided by Tiger Trade Technology Pte. Ltd.

Ardelyx

5.43
+0.12002.26%
Volume:1.08M
Turnover:5.86M
Market Cap:1.33B
PE:-21.25
High:5.51
Open:5.43
Low:5.36
Close:5.31
52wk High:8.40
52wk Low:3.21
Shares:245.25M
Float Shares:232.53M
Volume Ratio:1.25
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2556
EPS(LYR):-0.2556
ROE:-36.21%
ROA:-5.46%
PB:7.98
PE(LYR):-21.25

Loading ...

Stock Track | Ardelyx Soars 28.34% on Strong Q3 Results and Raised IBSRELA Guidance

Stock Track
·
Oct 31, 2025

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Oct 31, 2025

Ardelyx Q3 Breakeven, Revenue Increases; Shares Rise Pre-Bell

MT Newswires Live
·
Oct 31, 2025

Stock Track | Ardelyx Surges 14.37% Pre-Market on Strong Q3 Results and Raised IBSRELA Guidance

Stock Track
·
Oct 31, 2025

Stock Track | Ardelyx Soars 14.37% Pre-Market on Strong Q3 Results and Raised IBSRELA Guidance

Stock Track
·
Oct 31, 2025

Stock Track | Ardelyx Soars 16.77% on Strong Q3 Results and Raised IBSRELA Guidance

Stock Track
·
Oct 31, 2025

Stock Track | Ardelyx Soars 16.77% After Strong Q3 Results and Raised IBSRELA Guidance

Stock Track
·
Oct 31, 2025

Ardelyx’s Strong Market Performance and Growth Potential Justify Buy Rating and Raised Price Target

TIPRANKS
·
Oct 31, 2025

Stock Track | Ardelyx Soars 14.37% After Hours on Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 31, 2025

Stock Track | Ardelyx Soars 14.37% After-Hours on Strong Q3 Results and Raised Guidance

Stock Track
·
Oct 31, 2025

Ardelyx Q3 Sales $110.329M Beat $100.878M Estimate

Benzinga
·
Oct 31, 2025

BRIEF-Ardelyx Q3 Operating Income USD 4.668 Million

Reuters
·
Oct 31, 2025

Ardelyx Q3 Product Sales USD 105.515 Million

THOMSON REUTERS
·
Oct 31, 2025

Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Oct 31, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30, 2025

Ardelyx presents data on IBSRELA at ACG annual scientific meeting

TIPRANKS
·
Oct 28, 2025

Ardelyx Reports IBSRELA Reduces Healthcare Visits in IBS-C Patients

Reuters
·
Oct 28, 2025

Ardelyx’s Phase 3 Study on Tenapanor: A Potential Game-Changer for Pediatric IBS-C

TIPRANKS
·
Oct 28, 2025

Ardelyx Showcases New XPHOZAH Data for Hyperphosphatemia in Dialysis Patients at ASN Kidney Week

Reuters
·
Oct 21, 2025

Ardelyx Inc. Files Initial Beneficial Ownership Statement for Chief Medical Officer Edward R. Conner

Reuters
·
Oct 18, 2025